Loading patent…
AssigneeGov. of the USA, represented by the Secretary , Depa.
InventorsWarren J. Leonard, Katsutoshi Ozaki, Rosanne Spolski, Herbert C. Morse, Peter E. Lipsky, Derry Roopenian
Estimating the term…
A transgenic mouse is disclosed herein whose somatic and germ cells comprise a disrupted IL-21 receptor gene, the disruption being sufficient to inhibit the binding of IL-21 to an IL-21 receptor, and a disrupted IL-4 gene, the disruption being sufficient to inhibit the production of IL-4 or the binding of IL-4 to the IL-4 receptor. A mouse homozygous for the disrupted IL-21 receptor gene and homozygous for the disrupted IL-4 gene has diminished B cell function. A method is disclosed for altering a B cell activity. The method includes administering a therapeutically effective amount of an agent that interferes with the interaction of IL-21 with an IL-21 receptor, thereby altering the B cell activity. A method is also disclosed for of treating a subject with Job's disorder or atopic disease. A method is also disclosed for treating or preventing an allergic reaction in a subject. A method is also disclosed for treating a subject with an autoimmune or antibody mediated disorder.
A transgenic mouse whose somatic and germ cells comprise a disrupted IL-21 receptor gene, the disruption being sufficient to inhibit the binding of IL-21 to an IL-21 receptor, and a disrupted IL-4 gene, the disruption being sufficient to inhibit the production of IL-4 or the binding of IL-4 to the IL-4 receptor, the disrupted IL-21 receptor and IL-4 genes being introduced into the mouse or an ancestor of the mouse at an embryonic stage, wherein a mouse homozygous for the disrupted IL-21 receptor gene and homozygous for the disrupted IL-4 gene has diminished B cell function.
A method of altering a B cell activity, comprising
A method of treating a subject with Job's disorder or atopic disease, comprising administering to the subject a therapeutically effective amount of IL-21 or an agonist thereof, thereby ameliorating a sign or a symptom of Job's disorder or atopic disease.
A method of treating or preventing an allergic reaction in a subject, comprising administering to the subject a therapeutically effective amount of an agent that inhibits the interaction of IL-21 with its receptor or inhibits IL-21 induced signaling, thereby treating or preventing the allergic reaction.
A method of treating an IL-4 mediated disorder in a subject, comprising administering to the subject a therapeutically effective amount of IL-21 or an agonist thereof.
Dependencies are inferred from the claim text.